Education
About Us
Working with TipRanks
Follow Us
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
RESEARCH TOOLSreports
Total Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a market cap or net worth of HK$18.50B. The enterprise value is HK$7.91B.
Market CapHK$18.50B
Enterprise ValueHK$7.91B
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding220,094,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 4.12%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.12%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee2.74M
Profits Per Employee324.46K
Employee Count1,926
Asset Turnover0.30
Inventory Turnover0.65
Valuation Ratios
The current PE Ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is 19.3. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s PEG ratio is ―.
PE Ratio19.3
PS Ratio―
PB Ratio―
Price to Fair Value0.45
Price to FCF―
Price to Operating Cash Flow10.74
PEG Ratio―
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H had revenue of 5.28B and earned 646.74M in profits. Earnings per share was 0.44.
Revenue5.28B
Gross Profit1.76B
Operating Income741.31M
Pretax Income726.23M
Net Income646.74M
EBITDA1.20B
Earnings Per Share (EPS)0.44
Cash Flow
In the last 12 months, operating cash flow was 1.05B and capital expenditures -39.95M, giving a free cash flow of 1.75B billion.
Operating Cash Flow1.05B
Free Cash Flow1.75B
Free Cash Flow per Share7.96
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays an annual dividend of HK$0.272, resulting in a dividend yield of 4.58%
Dividend Per ShareHK$0.272
Dividend Yield4.58%
Payout Ratio89.95%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change87.66%
50-Day Moving Average6.18
200-Day Moving Average4.68
Relative Strength Index (RSI)42.54
Average Volume (3m)2.75M
Important Dates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H upcoming earnings date is Oct 29, 2025, TBA (Not Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend DateMay 26, 2025
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H as a current ratio of 2.60, with Debt / Equity ratio of 19.49%
Current Ratio2.60
Quick Ratio1.14
Debt to Market Cap0.54
Net Debt to EBITDA1.08
Interest Coverage Ratio5.25
Taxes
In the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has paid 101.31M in taxes.
Income Tax101.31M
Effective Tax Rate0.14
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H EV to EBITDA ratio is 5.63, with an EV/FCF ratio of 3.39.
EV to Sales1.28
EV to EBITDA5.63
EV to Free Cash Flow3.39
EV to Operating Cash Flow3.07
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has HK$3.06B in cash and marketable securities with HK$2.37B in debt, giving a net cash position of -HK$692.36M billion.
Cash & Marketable SecuritiesHK$3.06B
Total DebtHK$2.37B
Net Cash-HK$692.36M
Net Cash Per Share-HK$3.15
Tangible Book Value Per ShareHK$6.43
Margins
Gross margin is 31.29%, with operating margin of 14.04%, and net profit margin of 12.25%.
Gross Margin31.29%
Operating Margin14.04%
Pretax Margin13.75%
Net Profit Margin12.25%
EBITDA Margin22.70%
EBIT Margin16.43%
Analyst Forecast
The average price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is HK$4.31, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price TargetHK$4.31
Price Target Upside-27.32% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-6.14%
EPS Growth Forecast―